Darifenacin CAS 133099-04-4 Powder Raw Materials

Related Attributes

Product details

Darifenacin Powder Usage and Synthesis:

Darifenacin  The current clinical use of Powder for the treatment of hyperactivity syndrome consists mainly of anticholinergic receptor drugs. These drugs are mostly non-selective, such as tolterodine or less selective, such as oxybuty-nin, which block not only the M3 receptor in the detrusor muscle, but also other receptors Somatic subtypes, such as M1 receptors that affect cognitive function and M2 receptors that affect myocardial function, cause many adverse reactions in the treatment of OAB. Darifenacin CAS 133099-04-4 is a competitive muscarinic M3 receptor antagonist for the treatment of overactive bladder (OAB) patients with symptoms of urge incontinence, urgency to urinate, and frequency of urination. It has the characteristics of good efficacy, good tolerance and less adverse reactions. It is clinically used to improve symptoms such as frequency, urgency and incontinence caused by overactive bladder disorder (OAB). This product is a selective muscarinic M3 receptor antagonist. This product is intended to relieve symptoms of overactive bladder (OAB), such as frequent urination, urgency to urinate and incontinence.

Pharmacokinetics of Darifenacin Powder:

The oral bioavailability of Darifenacin Powder was 15% to 19%, and food had no effect on absorption. The blood concentration of healthy volunteers reached the peak about 7h after taking Daphenaxin sustained-release tablets with multiple doses, and the blood concentration reached stable state after continuous administration for 6 days. The binding rate of dapinaxine plasma protein was about 98%, which was mainly bound to α1-acid glycoprotein, and the steady-state apparent distribution volume was about 163L. Dapinaxine is metabolized by CYP2D6 and CYP3A4 of the liver microsomal somatic pigment P450 enzyme system, and the main metabolites have no physiological activity. 60% of Dapinaxine was excreted by kidney, 40% by feces, mainly in the form of metabolites, not metabolized maternal drugs accounted for only 3%, the clearance rate of 32 ~ 40L, elimination half-life of about 13 ~ 19h.

Clinical Application of Darifenacin Powder:

Darifenacin Powder is a drug raw material for the treatment of overactive bladder syndrome. Darifenacin CAS 133099-04-4  Raw Materials are white powders. Darifenacin Powder is suitable for improving symptoms such as urinary frequency,  urgency and urinary incontinence caused by overactive bladder (OAB). China Darifenacin Powder Supplier and Manufacturer.

Name :Darifenacin

Synonyms :CS-773; 2 - (1 - (2 - (2, 3 - Dihydrobenzofuran - 5 - yl) baton rouge) pyrrolidin - 3 - yl) - 2 - diphenylacetaMide; UK88525; UK88525; UK-88525; 2 - {3 s) - 1 - [2 - (2, 3 - dihydro - 1 - benzofuran - 5 - yl) baton rouge] pyrrolidin - 3 - yl} - 2, 2 - dip; Darifenacin,> = 98%; DARIFENACIN

CAS number :133099-04-4

Molecular formula :C28H30N2O2

Molecular weight :426.55

Why choose us?

HRK Factory

About Shipping